Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stake Cut by Sapient Capital LLC

Sapient Capital LLC reduced its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 56.6% in the 4th quarter, Holdings Channel reports. The fund owned 3,540 shares of the biotechnology company’s stock after selling 4,615 shares during the period. Sapient Capital LLC’s holdings in Sarepta Therapeutics were worth $430,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of SRPT. Wellington Management Group LLP lifted its stake in Sarepta Therapeutics by 32.3% in the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock worth $340,527,000 after acquiring an additional 665,087 shares in the last quarter. Erste Asset Management GmbH purchased a new stake in shares of Sarepta Therapeutics during the 3rd quarter worth about $79,425,000. Janus Henderson Group PLC raised its stake in shares of Sarepta Therapeutics by 14.2% during the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock worth $544,408,000 after purchasing an additional 543,143 shares in the last quarter. Soros Fund Management LLC purchased a new stake in shares of Sarepta Therapeutics during the 3rd quarter worth about $25,800,000. Finally, Swedbank AB purchased a new stake in shares of Sarepta Therapeutics during the 4th quarter worth about $16,706,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $109.68 on Wednesday. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The company has a market capitalization of $10.48 billion, a PE ratio of 87.74 and a beta of 0.75. Sarepta Therapeutics, Inc. has a one year low of $102.15 and a one year high of $173.25. The business has a 50 day simple moving average of $120.49 and a 200 day simple moving average of $125.33.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the transaction, the director now owns 5,880 shares in the company, valued at approximately $738,234. The trade was a 21.77 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the transaction, the director now owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. The trade was a 31.49 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Cantor Fitzgerald raised Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $152.00 to $167.00 in a research note on Thursday, November 7th. StockNews.com lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $182.00 target price on shares of Sarepta Therapeutics in a report on Monday, October 21st. Robert W. Baird lowered their target price on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. Finally, Needham & Company LLC reissued a “buy” rating and set a $202.00 price objective on shares of Sarepta Therapeutics in a report on Monday, January 27th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $176.77.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.